Thrombocythemia, Essential: Clinical Trials

88 trials for Thrombocythemia, Essential, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

52 completed, 12 terminated, 10 recruiting, 8 active not recruiting. 88 Phase 2, 23 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 288Completed 52, Terminated 12, Recruiting 10, Active not recruiting 8, Unknown 3, Withdrawn 3
Phase 123Completed 16, Recruiting 2, Withdrawn 2, Active not recruiting 1, Terminated 1, Unknown 1
Phase 32Completed 1, Terminated 1

Follow Thrombocythemia, Essential: new trials by email Literature Review of Thrombocythemia, Essential trials Research Report on Thrombocythemia, Essential

Trials (filtered) newest first · largest first

All 88 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm
Phase 2RecruitingNational Cancer Institute (NCI)782025-08-142026-11-16
A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial
STP938 - Essential Thrombocythaemia
Phase 2RecruitingStep Pharma, SAS502025-06-182026-06-16
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
JBI-802 - Essential Thrombocythemia (ET), Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
Phase 1 / Phase 2RecruitingJubilant Therapeutics Inc.302024-10-212026-06-03
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
Methotrexate (MTX) - Polycythemia Vera (PV), Essential Thrombocythemia (ET)
Phase 2RecruitingIcahn School of Medicine at Mount Sinai542024-10-022025-12-17
Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET
Peginterferon α-2b injection - Essential Thrombocythemia
Phase 2RecruitingXiamen Amoytop Biotech Co., Ltd.272024-08-292025-11-17
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia
Phase 2RecruitingUniversity of Southern California302024-03-012026-03-27
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Ropeginterferon alfa-2b-njft (P1101) - Essential Thrombocythemia
Phase 2Active not recruitingPharmaEssentia912022-09-292025-08-13
Ruxolitinib in Thrombocythemia and Polycythemia Vera
Ruxolitinib - Essential Thrombocythemia, Polycythemia Vera
Phase 2RecruitingMassachusetts General Hospital602022-03-212026-01-08
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
N-Acetylcysteine - Myeloproliferative Neoplasm, MPN
Phase 1 / Phase 2RecruitingUniversity of California, Irvine272022-01-032026-03-10
An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)
Bomedemstat - Thrombocythemia, Essential, Primary Myelofibrosis
Phase 2CompletedImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)812021-12-152025-09-22
Two Step Haplo With Radiation Conditioning
Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 2RecruitingThomas Jefferson University632021-10-252025-10-30
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg - Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET)
Phase 2CompletedOttawa Hospital Research Institute442021-02-172024-05-29
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
IMG-7289 - Essential Thrombocythemia, Polycythemia Vera
Phase 2Active not recruitingTerrence J Bradley, MD42020-10-022026-01-07
Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)
Bomedemstat - Essential Thrombocythemia
Phase 2CompletedImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)732020-09-082026-05-04
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2
IMG-7289 - Thrombocythemia, Essential
Phase 2Active not recruitingThe University of Texas Health Science Center at San Antonio92020-04-092026-10-22
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Decitabine, Ruxolitinib, Fedratinib - Acute Myeloid Leukemia, Essential Thrombocythemia
Phase 2RecruitingUniversity of Washington252020-03-242026-09-17
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia
Recombinant Interferon Alpha, Pegylated interferon alfa-2b - Essential Thrombocytopenia
Phase 2UnknownInstitute of Hematology & Blood Diseases Hospital, China402020-01-102024-07-03
Dual Vaccine Trial in Myeloproliferative Neoplasms
PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL, Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL - Polycythemia Vera, Essential Thrombocythemia
Phase 1 / Phase 2CompletedInge Marie Svane92019-07-102023-07-13
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Azacitidine, Pevonedistat, Venetoclax - Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center402019-02-272026-07-16
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib - Essential Thrombocythemia, Myelofibrosis
Phase 1 / Phase 2TerminatedOhio State University Comprehensive Cancer Center122019-02-202026-04-24

Showing 20 of 88. Sign in to see all of them.

Narrower conditions

Polycythemia Vera (73)  ·  Primary Myelofibrosis (64)  ·  Myeloproliferative Disorders (56)  ·  Leukemia, Myeloid, Acute (31)  ·  Leukemia, Myelomonocytic, Chronic (30)  ·  Myelodysplastic Syndromes (29)  ·  Leukemia (26)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (26)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (25)  ·  Multiple Myeloma (22)  ·  Leukemia, Myeloid, Accelerated Phase (21)  ·  Lymphoma, Non-Hodgkin (21)  ·  Blast Crisis (20)  ·  Congenital Abnormalities (20)

Broader conditions

Hemic and Lymphatic Diseases (88)  ·  Blood Coagulation Disorders (86)  ·  Blood Platelet Disorders (86)  ·  Hemorrhagic Disorders (86)  ·  Bone Marrow Diseases (84)  ·  Thrombocytosis (83)  ·  Hematologic Diseases (82)  ·  Neoplasms by Site (75)  ·  Bone Marrow Neoplasms (73)  ·  Hematologic Neoplasms (73)  ·  Neoplasms (73)  ·  Neoplasms by Histologic Type (41)  ·  Leukemia, Myeloid (40)  ·  Chronic Disease (39)  ·  Disease Attributes (39)

Interventions

fludarabine phosphate (19)  ·  Cyclophosphamide (18)  ·  Peripheral Blood Stem Cell Transplantation (16)  ·  Busulfan (14)  ·  Whole-Body Irradiation (11)  ·  Cyclosporine (10)  ·  Methotrexate (10)  ·  Mycophenolic Acid (10)  ·  Tacrolimus (10)  ·  ruxolitinib (8)  ·  Antilymphocyte Serum (7)  ·  fludarabine (6)  ·  Radiotherapy (5)  ·  Biopsy (4)  ·  bomedemstat (4)

Sponsors

Fred Hutchinson Cancer Center (11)  ·  National Cancer Institute (NCI) (6)  ·  M.D. Anderson Cancer Center (5)  ·  Mayo Clinic (4)  ·  H. Lee Moffitt Cancer Center and Research Institute (3)  ·  Italfarmaco (3)  ·  Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (2)  ·  OHSU Knight Cancer Institute (2)  ·  Ronald Hoffman (2)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2)  ·  Sierra Oncology LLC - a GSK company (2)  ·  Asan Medical Center (1)  ·  Baylor College of Medicine (1)  ·  Cancer Treatment Centers of America (1)  ·  Case Comprehensive Cancer Center (1)

Countries

United States (66)  ·  Germany (11)  ·  Italy (10)  ·  United Kingdom (10)  ·  France (9)  ·  Australia (7)  ·  Canada (6)  ·  Belgium (3)  ·  Denmark (3)  ·  Netherlands (3)  ·  Switzerland (3)  ·  China (2)  ·  Hong Kong (2)  ·  New Zealand (2)  ·  Poland (2)

Top investigators

Ruben A. Mesa, MD (4)  ·  Alessandro Rambaldi, MD (3)  ·  H. Joachim Deeg, MD (2)  ·  Jorge Cortes, MD (2)  ·  Teresa Field, MD, PhD (2)  ·  Uday Popat, MD (2)  ·  Usama Gergis, MD (2)  ·  Albert Assad, MD (1)  ·  Amy E DeZern, MD (1)  ·  Anand A Patel (1)  ·  Andrew Roberts, M.D. (1)  ·  Angela Fleischman, MD, PhD (1)  ·  Ann E. Woolfrey, MD (1)

Results publications

PMID 32499241, PMID 11468154, PMID 19841031, PMID 20651074, PMID 22943924, PMID 24362550, PMID 24903629, PMID 25563429, PMID 25762180, PMID 26210442, PMID 26332546, PMID 27479177, PMID 28291640, PMID 28622623, PMID 29152412, PMID 30409796, PMID 30630975, PMID 32634234, PMID 32732354, PMID 33609248, PMID 36564535, PMID 36881782, PMID 36911725, PMID 37422688, PMID 37530627, PMID 37592092, PMID 38259250, PMID 40330782, PMID 40775758, PMID 41758981, PMID 42306077, PMID 9326205

NIH funding

P30CA015083 (4), P01CA015396 (2), P01CA018029 (2), P01CA108671 (2), P30CA006973 (2), P30CA015704 (2), 2004 (1), 2018 (1), 2019 (1), N01CM17104 (1), N01CM62201 (1), P01CA078902 (1), P30CA014089 (1), P30CA014599 (1), P30CA016058 (1)